A new report, the 2012 Pharmaceutical R&D Factbook, from Thomson Reuters says that pharma R&D may be (finally) improving. According to their analysis, NMEs have soared to 31 launched in 2011, nearly double the rate from five years ago.
Many of the drugs were for significant medical issues like cancer, hepatitis C or lupus. In 2011, the standout companies were Roche, BMS, GSK, Merck and Vertex.
Pharma’s still up against the patent cliff. Last year, the industry generated record sales of $880 billion, but it can’t replace those sales fast enough as blockbusters go generic. Even pharmaco’s getting into the generics game hasn’t slowed the erosion enough to make an impact. This report should provide some amount of cautious optimism.
"The pharmaceutical industry touches all of our lives, whether directly or indirectly. Having insight into the drivers of the outcomes in Pharma R&D is critical in planning strategies and operational improvements," said Jon Brett-Harris, executive vice president, Thomson Reuters. "This year's Factbook provides a unique view into the industry at a point when many pharma leaders are developing new strategies for growth. It unveils our thought-leaders' findings from extensive and proprietary data and is a valuable resource for clinical operations, project management, portfolio managers, licensing executives, venture capitalists, and pharmaceutical executives alike."
Link: Thomson Reuters press release
No comments:
Post a Comment